Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Ligand Pharmaceuticals

- PMLiVE

WHO calls for better medicines access to close neurological disorders treatment gap

In 2021, neurological conditions affected more than three billion people worldwide

- PMLiVE

WHO publishes new toolkit to improve services for neurological disorders

Neurological conditions such as dementia and stroke were responsible for more than three billion cases globally in 2021

- PMLiVE

Takeda shares long-term results for HyQvia in rare neurological disorder CIDP

The therapy is the first and only facilitated subcutaneous immunoglobulin treatment for CIDP

- PMLiVE

Study reveals two copies of APOE4 gene could increase risk of developing Alzheimer’s

The progressive neurodegenerative disease is the most common form of dementia

- PMLiVE

AbbVie to expand neuroscience pipeline with $8.7bn Cerevel Therapeutics acquisition

The deal includes a candidate currently in phase 3 testing as a treatment for Parkinson’s disease

- PMLiVE

CureVac advances ‘promising’ seasonal flu mRNA vaccine to phase 2 development

The mid-stage study of the candidate is expected to begin in the fourth quarter of 2023

- PMLiVE

COVID-19 linked to long-term neurologic disorders in new US study

Those infected with the virus had a 77% higher risk of developing memory problems versus control groups

- PMLiVE

FDA approves GSK’s Priorix vaccine for measles, mumps and rubella

The vaccine has been approved to use in those aged 12 months and above

- PMLiVE

Rare cancer specialists Sierra Oncology acquired by GSK for £1.5bn

Unification will help to uphold and progress promising Momelotinib treatment which targets myelofibrosis

- PMLiVE

GSK and CureVac sign deal with Germany for mRNA COVID-19 vaccines

The agreement is part of a Pandemic Preparedness Contract and means millions of vaccines can be produced at short notice during future public health emergencies

dengue fever mosquito

WHO has recommended GSK’s malaria vaccine for children

This is the first and only malaria vaccine to have been shown in pivotal long-term clinical trials to significantly reduce malaria in children

- PMLiVE

GSK beats expectations thanks to strong vaccine sales in Q2

GSK's vaccine business was up by 39% to £1.6bn thanks to the strong growth (46%) of its meningitis vaccine

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links